Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://surfingtheapocalypse.net
Are you over 18 and want to see adult content?
A complete backup of https://06242.ua
Are you over 18 and want to see adult content?
A complete backup of https://grobo.io
Are you over 18 and want to see adult content?
A complete backup of https://rsrenterprises.online
Are you over 18 and want to see adult content?
A complete backup of https://atomicdust.info
Are you over 18 and want to see adult content?
A complete backup of https://pharma-food.de
Are you over 18 and want to see adult content?
A complete backup of https://chiflat-iron.us
Are you over 18 and want to see adult content?
A complete backup of https://mhsinc.org
Are you over 18 and want to see adult content?
A complete backup of https://luneproduction.com
Are you over 18 and want to see adult content?
A complete backup of https://beta-i.pt
Are you over 18 and want to see adult content?
A complete backup of https://saintlouischessclub.org
Are you over 18 and want to see adult content?
A complete backup of https://eachshoes.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of onlinestudienzentrum.de
Are you over 18 and want to see adult content?
A complete backup of takaritokommando.hu
Are you over 18 and want to see adult content?
A complete backup of lancerinsurance.com
Are you over 18 and want to see adult content?
A complete backup of profaceamerica.com
Are you over 18 and want to see adult content?
A complete backup of webdevchallenges.com
Are you over 18 and want to see adult content?
A complete backup of lesobservateurs.ch
Are you over 18 and want to see adult content?
Text
lives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaignORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password HORIZON - MERCK & CO. THIS IS A RESTRICTED GATEWAY. ANYONE GAINING UNAUTHORIZED ACCESS WILL BE SUBJECT TO PROSECUTION. Please choose either Horizon Client or VMware Horizon HTML Access and sign in to begin your secure session. INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaignORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password HORIZON - MERCK & CO. THIS IS A RESTRICTED GATEWAY. ANYONE GAINING UNAUTHORIZED ACCESS WILL BE SUBJECT TO PROSECUTION. Please choose either Horizon Client or VMware Horizon HTML Access and sign in to begin your secure session. INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards MERCK ANNOUNCES SUPPLY AGREEMENT WITH U.S. GOVERNMENT FOR U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). MEET THE TEAM LEADING OUR COVID-19 VACCINE PARTNERSHIP We’re proud to collaborate with Johnson & Johnson on the production of vital COVID-19 vaccine doses. When the news broke, our teams were already hard at work on preparations, thanks to leaders like Amanda Taylor and Kim Dezura, who help keep our Durham, North Carolina, and West Point, Pennsylvania, plants running smoothly. POLICIES & POSITIONS Merck policies and positions help achieve business objectives responsibly. Merck aspires to be the premier research-intensive biopharmaceutical company. INTRODUCING OUR GLOBAL HYBRID WORKING MODEL Over the last year, the global pandemic has created profound challenges — for the world, for our industry, for our own families. We are proud and grateful to see how the people of our company have looked out for each other and carried out our urgent mission on behalf of our customers and patients. GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaign THE ROAD FORWARD: CEOS ON THE RETURN OF LEISURE AND TRAVEL Responsibility The road forward: CEOs on the return of leisure and travel. In this Teal Talks episode, leaders discuss how the cinema, restaurant and cruise industries are poised for a comeback in the era of COVID-19 vaccinationsPHILANTHROPY
The Inn provides housing for seriously ill children undergoing treatment at the NIH. We have provided more than $19M to support the initial construction, expansion and general operations of The Inn in Bethesda, Maryland. Since its opening in 1990, The Inn has UNDERSTANDING THE LINK BETWEEN SOCIAL MEDIA AND HEALTH Innovation Understanding the link between social media and health. The Alliance for Advancing Health Online will look at social media’s role in health, starting with COVID-19 3 WAYS WE SUPPORT THE LGBTQ+ COMMUNITY A unique approach to employee outreach. Many companies offer resource groups for employees, but our company goes a step further. We’ve taken a pioneering and global approach to our diversity strategy through the creation of Employee Business Resource Groups (EBRGs), including the Merck Rainbow Alliance. WHY YOUNG PROFESSIONALS WANT TO GROW THEIR CAREERS WITH US For Aadi Mhatre, a 2019 graduate of Carnegie Mellon University, finding a company that valued an employee’s long-term future was key. “As the first step in my career, I wanted to make sure that I was setting myself up for success,” says Aadi, now a specialist in global vaccines technical operations. MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
ORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portionsORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards HORIZON - MERCK & CO. THIS IS A RESTRICTED GATEWAY. ANYONE GAINING UNAUTHORIZED ACCESS WILL BE SUBJECT TO PROSECUTION. Please choose either Horizon Client or VMware Horizon HTML Access and sign in to begin your secure session.VARIVAX - MERCK
VARIVAX® 9548903
Refrigerator-stable formulation 2 Clinical Data in Children One-Dose Regimen in Children In combined clinical trials5 of varicella vaccine (Oka/Merck) at doses ranging from 1000 to 17,000 PFU, the majority of subjects who received the vaccine and were exposed to wild-type viruswere either
HIGHLIGHTS OF PRESCRIBING INFORMATION KEYTRUDA FOR THE Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, asdetermined by an FDA-approved test, that haveprogressed
MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
ORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portionsORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards HORIZON - MERCK & CO. THIS IS A RESTRICTED GATEWAY. ANYONE GAINING UNAUTHORIZED ACCESS WILL BE SUBJECT TO PROSECUTION. Please choose either Horizon Client or VMware Horizon HTML Access and sign in to begin your secure session.VARIVAX - MERCK
VARIVAX® 9548903
Refrigerator-stable formulation 2 Clinical Data in Children One-Dose Regimen in Children In combined clinical trials5 of varicella vaccine (Oka/Merck) at doses ranging from 1000 to 17,000 PFU, the majority of subjects who received the vaccine and were exposed to wild-type viruswere either
HIGHLIGHTS OF PRESCRIBING INFORMATION KEYTRUDA FOR THE Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, asdetermined by an FDA-approved test, that haveprogressed
MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable MERCK ANNOUNCES SUPPLY AGREEMENT WITH U.S. GOVERNMENT FOR U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482).MSD ACCOUNT
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. DISCOVER JOB OPPORTUNITIES AT MERCK 71k. Approximate number of employees. $9.9B. 2019 research & development investment. $2.8B. Philanthropy. We are one company, but we operate under two different corporate brand names. We are known as Merck & Co., Inc., Kenilworth, New Jersey, USA in the United States, Canada & Puerto Rico. We are known as MSD everywhere else. OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaign UNDERSTANDING THE LINK BETWEEN SOCIAL MEDIA AND HEALTH Innovation Understanding the link between social media and health. The Alliance for Advancing Health Online will look at social media’s role in health, starting with COVID-19PHILANTHROPY
The Inn provides housing for seriously ill children undergoing treatment at the NIH. We have provided more than $19M to support the initial construction, expansion and general operations of The Inn in Bethesda, Maryland. Since its opening in 1990, The Inn has MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password SIDE EFFECT ARCHIVES What is a clinical trial? A clinical trial is a research study in human volunteers that helps determine whether investigational vaccines, medicines, or new uses MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. MERCK AND RIDGEBACK BIOTHERAPEUTICS PROVIDE UPDATE ON Phase 3 MOVe-OUT Study of Molnupiravir in Outpatients to Proceed, Phase 2/3 MOVe-IN Study in Hospitalized Patients Will Not Proceed Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the clinical development program for molnupiravir (MK-4482/ EIDD-2801), an investigational orally available antiviral MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. MERCK AND RIDGEBACK BIOTHERAPEUTICS PROVIDE UPDATE ON Phase 3 MOVe-OUT Study of Molnupiravir in Outpatients to Proceed, Phase 2/3 MOVe-IN Study in Hospitalized Patients Will Not Proceed Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics today provided an update on the clinical development program for molnupiravir (MK-4482/ EIDD-2801), an investigational orally available antiviralORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password HIGHLIGHTS OF PRESCRIBING INFORMATION KEYTRUDA FOR THE Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, asdetermined by an FDA-approved test, that haveprogressed
POLICIES & POSITIONS Merck policies and positions help achieve business objectives responsibly. Merck aspires to be the premier research-intensive biopharmaceutical company. DISCOVER JOB OPPORTUNITIES AT MERCK 71k. Approximate number of employees. $9.9B. 2019 research & development investment. $2.8B. Philanthropy. We are one company, but we operate under two different corporate brand names. We are known as Merck & Co., Inc., Kenilworth, New Jersey, USA in the United States, Canada & Puerto Rico. We are known as MSD everywhere else. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable MERCK’S SARS-COV-2/COVID-19 EFFORTS: TIMELINE January 9, 2020 The WHO indicates that the infection is caused by a new type of coronavirus January 10 China shares the genetic code ofthe new virus
THE ROAD FORWARD: CEOS ON THE RETURN OF LEISURE AND TRAVEL Responsibility The road forward: CEOs on the return of leisure and travel. In this Teal Talks episode, leaders discuss how the cinema, restaurant and cruise industries are poised for a comeback in the era of COVID-19 vaccinations WHY YOUNG PROFESSIONALS WANT TO GROW THEIR CAREERS WITH US For Aadi Mhatre, a 2019 graduate of Carnegie Mellon University, finding a company that valued an employee’s long-term future was key. “As the first step in my career, I wanted to make sure that I was setting myself up for success,” says Aadi, now a specialist in global vaccines technical operations. UNDERSTANDING THE LINK BETWEEN SOCIAL MEDIA AND HEALTH Innovation Understanding the link between social media and health. The Alliance for Advancing Health Online will look at social media’s role in health, starting with COVID-19 3 WAYS WE SUPPORT THE LGBTQ+ COMMUNITY A unique approach to employee outreach. Many companies offer resource groups for employees, but our company goes a step further. We’ve taken a pioneering and global approach to our diversity strategy through the creation of Employee Business Resource Groups (EBRGs), including the Merck Rainbow Alliance. MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password SIDE EFFECT ARCHIVES What is a clinical trial? A clinical trial is a research study in human volunteers that helps determine whether investigational vaccines, medicines, or new uses MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, salesdeclined 1%.
MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaignORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions MERCK RECEIVES PRIORITY REVIEW FROM FDA FOR NEW DRUG Application Based on Objective Response Rate From Phase 2 Trial Evaluating Belzutifan in Patients With Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma New Filing Further Strengthens Merck’s Expanding and Diverse Oncology Portfolio Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, salesdeclined 1%.
MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaignORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions MERCK RECEIVES PRIORITY REVIEW FROM FDA FOR NEW DRUG Application Based on Objective Response Rate From Phase 2 Trial Evaluating Belzutifan in Patients With Von Hippel-Lindau Disease-Associated Renal Cell Carcinoma New Filing Further Strengthens Merck’s Expanding and Diverse Oncology Portfolio Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards PIPELINE - MERCK.COM No Duty to Update The information contained in this chart was current as of May 5, 2021. While this pipeline chart remains on the company’s website the company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the presentation and investors should not MEET THE TEAM LEADING OUR COVID-19 VACCINE PARTNERSHIP We’re proud to collaborate with Johnson & Johnson on the production of vital COVID-19 vaccine doses. When the news broke, our teams were already hard at work on preparations, thanks to leaders like Amanda Taylor and Kim Dezura, who help keep our Durham, North Carolina, and West Point, Pennsylvania, plants running smoothly. POLICIES & POSITIONS Merck policies and positions help achieve business objectives responsibly. Merck aspires to be the premier research-intensive biopharmaceutical company. INTRODUCING OUR GLOBAL HYBRID WORKING MODEL Over the last year, the global pandemic has created profound challenges — for the world, for our industry, for our own families. We are proud and grateful to see how the people of our company have looked out for each other and carried out our urgent mission on behalf of our customers and patients. MERCK ANNOUNCES COMPLETION OF ORGANON & CO. SPINOFF Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has completed the spinoff of Organon & Co. (Organon). “Today marks a significant milestone for both Merck and Organon. Organon is now an independent, publicly traded company with a broad portfolio of important medicines and products, and is fully prepared to deliver sustainable THE ROAD FORWARD: CEOS ON THE RETURN OF LEISURE AND TRAVEL Responsibility The road forward: CEOs on the return of leisure and travel. In this Teal Talks episode, leaders discuss how the cinema, restaurant and cruise industries are poised for a comeback in the era of COVID-19 vaccinations MERCK ANNOUNCES SUPPLY AGREEMENT WITH U.S. GOVERNMENT FOR 16 hours ago · U.S. government commits to purchase approximately 1.7 million courses of Molnupiravir upon issuance of Emergency Use Authorization or approval by the U.S. Food and Drug Administration Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced it has entered into a procurement agreement with the United States government for molnupiravir (MK-4482). 3 WAYS WE SUPPORT THE LGBTQ+ COMMUNITY A unique approach to employee outreach. Many companies offer resource groups for employees, but our company goes a step further. We’ve taken a pioneering and global approach to our diversity strategy through the creation of Employee Business Resource Groups (EBRGs), including the Merck Rainbow Alliance. WHY YOUNG PROFESSIONALS WANT TO GROW THEIR CAREERS WITH US For Aadi Mhatre, a 2019 graduate of Carnegie Mellon University, finding a company that valued an employee’s long-term future was key. “As the first step in my career, I wanted to make sure that I was setting myself up for success,” says Aadi, now a specialist in global vaccines technical operations. SIDE EFFECT ARCHIVES What is a clinical trial? A clinical trial is a research study in human volunteers that helps determine whether investigational vaccines, medicines, or new uses MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaignORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards HORIZON - MERCK & CO. THIS IS A RESTRICTED GATEWAY. ANYONE GAINING UNAUTHORIZED ACCESS WILL BE SUBJECT TO PROSECUTION. Please choose either Horizon Client or VMware Horizon HTML Access and sign in to begin your secure session. HIGHLIGHTS OF PRESCRIBING INFORMATION KEYTRUDA FOR THE Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, asdetermined by an FDA-approved test, that haveprogressed
MERCK | HOMEINVESTOR RELATIONSMERCK JOB OPPORTUNITIESPRODUCTS LISTCONTACT USCOMPANY At Merck, we're following the science to tackle some of the world's greatest health threats. Get a glimpse of how we work to improvelives.
MERCK ANNOUNCES ORGANON & CO. AS NEW COMPANY NAME FOR KENILWORTH, N.J., March 11, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Organon & Co. will be the name of the new company to be created through the intended spinoff of its women’s health, trusted legacy brands and biosimilars businesses. Organon has been an important part of Merck since the 2009 Schering-Plough acquisition. OUR FIRST-QUARTER 2021 FINANCIAL RESULTS Merck announced first-quarter sales of $12.1 billion, in-line with first-quarter 2020. Excluding the impact from foreign exchange, sales declined 1%. The company anticipates full-year 2021 revenue range to be between $51.8 billion and $53.8 billion, including a positive impact from foreign exchange of less than 2%. MERCK DECLARES RECORD DATE AND DIVIDEND FOR THE ORGANON Merck Announces Effectiveness of the Form 10 Registration Statement for Organon Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that its board of directors approved the separation of Organon & Co. (Organon), and declared a special dividend distribution of one-tenth of a share of Organon common stock for everyMerck common share
GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaignORGANON & CO.
Organon & Co. INFORMATION REQUIRED IN REGISTRATION STATEMENT CROSS-REFERENCE SHEET BETWEEN INFORMATION STATEMENT AND ITEMS OF FORM 10 Certain information required to be included herein is incorporated by reference to specifically identified portions MSD LOGIN - MERCK & CO. Enter your credentials. Username. Password INVESTOR RELATIONS FAQS ON ORGANON & CO. 7. When can I expect more information? Further details will be provided throughout the year, including on the timing on the Form 10 filing, the anticipated Organon & Co. debt offering and roadshow timing, and progress towards HORIZON - MERCK & CO. THIS IS A RESTRICTED GATEWAY. ANYONE GAINING UNAUTHORIZED ACCESS WILL BE SUBJECT TO PROSECUTION. Please choose either Horizon Client or VMware Horizon HTML Access and sign in to begin your secure session. HIGHLIGHTS OF PRESCRIBING INFORMATION KEYTRUDA FOR THE Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) solid tumors, asdetermined by an FDA-approved test, that haveprogressed
INTRODUCING OUR GLOBAL HYBRID WORKING MODEL Over the last year, the global pandemic has created profound challenges — for the world, for our industry, for our own families. We are proud and grateful to see how the people of our company have looked out for each other and carried out our urgent mission on behalf of our customers and patients. POLICIES & POSITIONS Merck policies and positions help achieve business objectives responsibly. Merck aspires to be the premier research-intensive biopharmaceutical company. PIPELINE - MERCK.COM Our pipeline provides an overview of our late-stage clinical development programs and is updated quarterly. V114 is an investigational vaccine currently being evaluated for its ability to provide protection against pneumococcal disease caused by serotypes contained in the vaccine. 1 - Being developed in collaboration. GABRIELLE UNION-WADE JOINS ‘DON’T SKIP’ CAMPAIGN TO New Public Health Campaign Spotlights the Importance of Staying Up to Date with Recommended Vaccinations Against Vaccine-Preventable Diseases WASHINGTON and KENILWORTH, N.J., May 17, 2021 – Vaccinate Your Family, in collaboration with Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the launch of a new public health campaignBOARD OF DIRECTORS
Our board of directors brings diverse perspectives, skills and areas of expertise important to fostering the company's business success. The board is dedicated to effective oversight of the business and the key risks facing the company. Kenneth C. Frazier. Leslie A. Brun. MaryEllen Coe.
SIDE EFFECT ARCHIVES What is a clinical trial? A clinical trial is a research study in human volunteers that helps determine whether investigational vaccines, medicines, or new uses DIVERSITY & INCLUSION Diversity and inclusion (D&I) are not just words – they are the reason we are able to deliver on our promise to invent for life. We foster a diverse workforce where employees feel comfortable bringing their unique perspectives to work. But diversity is only half of the story; inclusion is just as important. Inclusion means a sense ofbelonging.
NEW DATA ON KEYTRUDA® (PEMBROLIZUMAB) PLUS LENVIMA Results From New Analysis Evaluating Health-Related Quality of Life (HRQoL) Based on Patient-Reported Outcomes Using Three HRQoL Scales Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new investigational data from the pivotal Phase 3 CLEAR (Study 307)/KEYNOTE-581 trial, which evaluated the combinations of KEYTRUDA, MSD ANIMAL HEALTH TO ACQUIRE ASSETS OF LIC AUTOMATION LTD 1 day ago · Automated Technology Enhances Dairy Farm Management Builds on Strong MSD Animal Health Commitment to New Zealand Farmers Complements Broad MSD Animal Health Portfolio of Medicines, Vaccines and Technology Solutions MSD Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced its intention to acquire the assets of LIC NEIGHBOR OF CHOICE PROGRAM GUIDELINES January 2021 Program guidelines and participating sites Neighbor of Choice Program . Program criteria . Applicants must be nonprofit organizations with proven experience in implementing health, K-12 Science, Technology, Engineering, Mathematics (STEM) education, and environmental improvement*
* About Us
* About Us
* Corporate Responsibility* Leadership
* – Board of Directors * – Executive Committee* Our Work
* – Diabetes
* – HIV
* – Oncology
* – Vaccines
* Perspectives
* Confronting Unconscious Bias * A $16 Billion Investment in The Future * From the Military to Merck * Investing in Inclusive Business and Diverse Suppliers * Harnessing Digital Technology for Maternal Health * Helping Protect Generations From Preventable Infectious Diseases * Supporting Our Veterans: A Personal and Professional Commitment * We Can Grow Our Business While Protecting the Health of Our Planet * In the Fight Against Cancer, Progress is Made One Step at a Time * Advancing Oncology Research Through Clinical Trials * Taking Population Health to Merck Employees * How Merck is Working to Preserve One of the Planet’s Most VitalResources - Water
* Clear Communication Must be Part of the Care… and the Cure * Our Pricing Practices: Under the Microscope * Finding New Ways to Create a Healthier and More Sustainable World * When a Blockbuster Medicine Becomes a Generic * A Track Record of Responsible Pricing and Investing in the Next Generation of Inventions * From Pledge to Action: Diversity & Inclusion in Our Workplace * Diversity and Inclusion: Good for Business * Working Together to Create a Sustainable Market for Antibiotics* How We Operate
* – Code of Conduct * Our Values and Standards * Our Values and Standards For External Business Partners* – Compliance
* – Privacy
* – Transparency and Privacy * – Internet Privacy Policy * – Cookie Privacy Commitment * – Cross Border Policy * – Employment Privacy & Data Protection* – Diversity
* – Employee Diversity * – Programs and Partnerships * – Supplier Diversity * Chief Diversity Officer* What We Buy
* Definitions
* Register Potential Supplier * Supplier Diversity * Views and Positions * – Access and Affordability * – Access to Investigational Medicines* – Innovation
* – Quality and Safety * – Sales and Marketing * – Responsible Public Policy and Advocacy * Public Policy Position Statements * Trade Association Memberships* Our History
* Company Fact Sheet* Our People
* Featured Stories
* Meet Merck physician and volunteer Dr. Mo Ali * Our commitment to communities during the COVID-19 pandemic * Antibiotic resistance: the hidden threat lurking behind Covid-19 * Heart failure: A physician’s perspective * How our teams in China tackled early COVID-19 challenges * How Merck is responding to the global pandemic, COVID-19 * Women’s history month – a time to reflect and be inspired * My HPV Cancer Story * Black History Month — a time to reflect and celebrate * Podcast: How Merck is looking back on past epidemics and science to respond to the coronavirus outbreak * 5 ways to support a loved one living with lung cancer * Facing breast cancer three times – a profile of hope * Inside Davos 2020: the world economic forum * Merck joins the World Cancer Day movement to push for progress * Farm to boardroom: Leader Laura Villarreal is determined to keep animals and humans healthy * The power of partnership * Creating Safer Childbirth Cities: Leaning into our values of diversity and inclusion * How craft projects, talent shows and tai chi are helping people manage their diabetes in China * How our Boston Innovation Hub helps us build externalcollaborations
* How you can help slow the threat of antimicrobial resistance * The impact of family in managing type 2 diabetes * How 'hacking' may help solve some of health care's biggestchallenges
* How flexible workspaces are redefining the way we work * Five truths about lung cancer * Merck 2019 third-quarter financial results * Merck Publishes 2018/2019 Corporate Responsibility Report * Merck joins South San Francisco biotech community with innovative research site and hunger for collaboration * Antimicrobial resistance: a problem without a simple answer * A team approach to helping fight cancer * When breast cancer hits home * Inventing for life: passion, purpose and people * Meet Alan Northrup * ‘Embrace the gray areas…and dream big.’ * Meet Beth-Ann Coller * Tackling the U.S. maternal mortality crisis * Powered by inclusion: how we celebrate our diverse workforce * ‘You Never Forget That Day’ * How Jeron’s type 2 diabetes diagnosis motivated him to live ahealthy lifestyle
* How Don Watson builds diversity and inclusion into all aspects ofwork life
* Women in Leadership - Three supply chain leaders share theirstories
* Dr. Maurice Hilleman: The father of modern vaccines * Merck 2019 second-quarter financial results * Progress and purpose: a conversation with Merck scientists and HIVcare providers
* Meet two scientists whose goals are to help end the HIV epidemic * What you need to know about measles * Merck hosts students from INROADS College Links * Patients in remote areas are finding specialized care throughProject ECHO
* Meet our president leading the Asia Pacific region: DortheMikkelsen
* From factory to patient: Merck pilots blockchain project to traceand track drugs
* How Merck's historic discoveries in Palo Alto shape its future inSouth San Francisco
* How we are building a strong foundation in pancreatic cancerresearch
* Rising Star award winner Kara Price shares how she encouragesother women in STEM
* Making the healthy choice the easy choice for our employees* With Love, Me
* Driving melanoma research forward * Understanding melanoma * Meet the nurses who work at Merck * Merck 2019 first-quarter financial results * Merck’s cutting-edge facilities take manufacturing to newheights
* Women in Leadership * Living with and combating infectious diseases * ‘Scientific talent is everywhere, resources are not.’ * Infant Vaccination: A Public Health Success Story * Merck has ambitious goals to protect the environment * The Wonders of Water * Women in Leadership: Raquel Tapia * Advice from Women in Leadership * Helping Moms Safely Deliver Their Babies * Let’s Talk About Kidney Cancer * Pushing Forward in Prostate Cancer Research * Merck 2018 Fourth-Quarter and Full-Year Earnings * Women in Leadership: Geralyn Ritter * Merck Stands United on World Cancer Day * Inspiring People, One Day at a Time * Women in Leadership: Caroline Litchfield* We Are Honored
* Speeding Up Drug Discovery * Where Hope is an Anchor* Meet James Fells
* Dear Cancer Heroes: Honoring People in Clinical Trials * Ovarian cancer – too many lives cut short* Meet Caroline Fox
* Infectious Disease Week * Dr. Cathy Pietanza: ‘Each Day, I’m Reminded of My Patients’ * When Disaster Strikes * Merck Publishes 2017/2018 Corporate Responsibility Report * Fostering Work-Life Balance at Merck * Dave Hull Stands Up To Cancer * The Merck Fellowship for Global Health * Fostering Work-Life Balance at Merck * Meet Rob Garbaccio * Understanding Biomarkers: MicroSatellite Instability High/MisMatchRepair Deficiency
* National Immunization Awareness Month * What Cancers Have in Common: Pushing the Boundaries of Science* Meet John Howe
* Al Alberts, Key Figure in the "Cholesterol Revolution," Dies at 87 * Living with Type 2 Diabetes * Julie Gerberding Honored as 2018 Woman of the Year * Meet Stephanie Barrett * National Infant Immunization Week * Understanding Mumps * A Leader in Immuno-oncology Clinical Research * Meet Luis Zúñiga* HPV Awareness
* Your Cancer Game Plan Challenge* Meet Rebecca Ruck
* Employees Rising to the Occasion * Merck’s Employees Help After Disaster Strikes * Your Cancer Game Plan Lung * A very unique way to grow a family * Merck Publishes 2016/2017 Corporate Responsibility Report * World Diabetes Day 2017 * Meet Angela Jablonski * A Diagnosis of Breast Cancer * Your Cancer Game Plan Mike Schmidt * From Pledge to Action: Diversity & Inclusion in Our Workplace * The Unique Role of Public Policy in Addressing AntimicrobialResistance
* Merck’s Disaster Relief Efforts * Making Positive Choices * Pulling Back the Curtains on Insomnia * Creativity Inside a Shipping Container * Honoring Our Differences * Merck's Response to Hurricane Harvey * Merck Teams Up with Mandy Moore * The Vaccine Pioneers * Merck Stakes a Claim in Cambridge, Massachusetts * Aspen Ideas Festival* Dorothy Robinson
* Erika Carbray
* Nicole Pulli
* 2017 Merck Fellowship for Global Health * Our Legacy - And Future - in American Manufacturing * Merck's IT Organization Expands into Austin, Texas * MECTIZAN Donation Is One for the Record Books * Journey for Control * A Point of View by Dr. Bao Lam * Fighting Some of the World's Toughest Bacterial Infections* Meet Dan Cua
* It Takes a Village * Type 2 Diabetes: A Focus on A1C * May is for Mothers * Pushing to Outpace Superbugs * Merck Announces Enhancements to Family Leave Time * Classical Hodgkin Lymphoma: Facing Cancer in Young Adulthood* World Sleep Day
* BeKindAlways4Noah
* The Merck-Regenstrief Collaboration * Why Drug Discovery is the Foundation of Merck’s Future * How Chronic Hepatitis C is Impacting Our Veterans * Meet Gokul Swaminathan * Merck Honors Research Microbiologist H. Boyd Woodruff, Ph.D. * Merck Uses Amazon Web Services to Develop Voice-Enabled Solutions * Cancer Needs Cures. Still. * Merck Be Well Challenge 2016 — Bringing the Outside In * A Point of View by Adam Schechter, president of Global HumanHealth at Merck
* Your Cancer Game Plan * Merck Foundation Grant Helps Expand Project ECHO * Merck’s Commitment to Prevention and Care for NCDs* Meet Jay Schiller
* Merck Research Laboratories Expands into South San Francisco * Test. Talk. Take. Action. * Bridging the Gap in Diabetes Care * World Diabetes Day 2016 * Meet Harriet Johnson * Merck Employees Surpass Goal of 125,000 Volunteer Hours * _Merck for Mothers_ Pep Talk * Meet Commander Adam Scott* Meet Noreen Rizvi
* Ebola Outbreak
* A Point of View by Dr. Roger Dansey * A Point of View by Dr. Gregory Lubiniecki * Merck’s Susan Shiff Selected * Faces of the Future * Merck Research Laboratories Honored * Living with Breast Cancer* Health Literacy
* A Point of View by Julie Gerberding, M.D., M.P.H.* Meet Paige Cramer
* Merck Releases 2015/2016 Corporate Responsibility Report * How Merck Animal Health Helped to Curb a New Strain of CIV* Women in Science
* Meet Daria Hazuda
* Combating head and neck cancer * Understanding Head and Neck Cancer * HPV and Certain Cancers: What You Need to Know * Meet Arnaub Chatterjee * Fasting and Diabetes * Understanding Diabetes * Living with Type 2 Diabetes * It's Personal Series * Collaborating to Cure* Meet Mike Thien
* Roy Vagelos Honored by American Heart Association * Changing the Statistics * Charting a New Course in Cancer Care * New Approaches to Fighting Cancer * Melanoma... 'Never Walk Alone' * Be Safe In The Sun * America's Diabetes Challenge * World Immunization Week * Merck for Mothers at the Women in the World Summit * Vaccines: Our History, Our Legacy * The Impact of Cancer * Merck’s Commitment to Hepatitis C * Hepatitis C: A Silent Disease and Ongoing Concern * Using Water Wisely * Meet George W. Merck* Heart Disease
* Guided by Research, Inspired by Hope * Why Animal Health Matters* Merck Turns 125
* Cervical Health Awareness Month * Rallying to Meet the Need * William Campbell Wins Nobel Prize * Meet Christopher Kistler * Diversity and Inclusion: Good for Business * Understanding Alzheimer’s Disease* Living with HIV
* Meet Jason Cheung
* Hepatitis C: A Medical — and Social — Diagnosis * The Fight Against Hepatitis C * Saluting Those Who Serve * Lung Cancer: Challenges and Reasons for Hope* Real Invention
* World Diabetes Day* Lung Cancer
* Refugee and Migrant Relief Efforts * What is C. difficile * Beyond Tired? So Are They... * Meet Alexander Buitrago Santanilla * Ken Frazier Receives Lifetime Achievement Award * Merck Employees Walk to End Alzheimer’s * Ken Frazier at the Clinton Global Initiative * Helping to Advance a New Set of UN Global Goals * Merck Fellowship for Global Health * 2014 Corporate Responsibility Report * New Therapies to Attack Infections * The Race Against Resistance * Identifying the Next Generation of Antibacterial Therapies * The Fight Against Antimicrobial Resistance * Mectizan Donation Program * Meet Paul Reichert * Merck for Mothers at TEDWomen * Meet Spencer Dreher * Merck and HIV/AIDS * Fasting and Diabetes * Merck's Rule the Real Talk Campaign * Meet Daisy Richardson* Art for All
* MSD in Japan: Bringing Back the Beach * A Commitment to Diabetes Research * A Silent Disease and Growing Concern* Meet Tim Cernak
* Melanoma ... Never Walk Alone * Be Safe in the Sun * May is for Mothers * Bone Health Awareness * America's Diabetes Challenge * Pushing to Outpace Superbugs * The Evolution of Cancer Research * Parasites and Your Pets * Meet Ayesha Sitlani * Every Woman Every Child Event* Everyday Heroes
* New Approaches to Fighting Cancer* Insomnia
* Advancing Oncology Research Through Clinical Trials * Bridging the Gap in Diabetes Care * Closing the Circle on Rabies * Desafiando la Diabetes * Understanding Diabetes * Helping Empower Women Living with HIV * Diabetes and Travel * Vaccines: Our History, Our Legacy * The Impact of Cancer * A Point of View by Eric Rubin, M.D. * Making a Difference* Research
* Research
* Candidate Discovery * Preclinical Development * Clinical Development * Regulatory Review and Ongoing Monitoring * Our People, Our Culture * – The MRL Postdoctoral Research Fellow Program* Our R&D Process
* What We're Working On* Pipeline
* Clinical Trials
* Invent with Us
* Discover Where Our Research Happens* Products
* Products
* Product List A-Z
* Vaccines & Prescribing Information * Prescription Products & Prescribing Information * Oncology Products & Prescribing Information* Animal Health
* Access and Patient Assistance* Product Patents
* Authorized Distributors * Vaccine Contracted Distributors * Safety Data Sheets (SDS)* Careers
* Careers
* Search Jobs
* Our Divisions
* – Research & Development * – Manufacturing & Supply* – Human Health
* – Animal Health
* – Global Support Functions * Diversity & Inclusion * Compensation & Benefits * Veterans Opportunities * Student Opportunities* How We Hire
* MSD Careers
* Talent Community
* Events
* Investors
* Investors
* Product Pipeline
* News
* Events & Presentations* Stock Info
* – Stock Quote & Chart * – Historical Price Look-up * – Investment Calculator * – Dividend History* – Stock Splits
* – Analyst Coverage* Financials
* – Quarterly Reports * – Annual Reports & Proxy* – SEC Filings
* Governance
* Investor Resources* – FAQs
* – Stockholder Services * – Corporate Responsibility * – Information Request * – Sign up for Email Alerts* – Other
* – Contact Us
* Newsroom
* Newsroom
* News Releases
* – Prescription Medicine News * – Consumer Care News* – Vaccine News
* – Research & Development News * – Corporate News * – Financial News * – Corporate Responsibility News * – Animal Health News * Information Centers* – Diabetes
* – Ebola
* – Oncology
* Company Statements* Media Center
* Company Snapshot
* Social Media
* Licensing
* Licensing
* Contact Us
* Contact Us
* FAQ
*
* WORLDWIDE
*
Contact Us
* Contact Us
* FAQ
*
* Information Center×
* COVID-19
* Navigation
* About Us
×
About Us
* About Us
* Corporate Responsibility* Leadership
* – Board of Directors * – Executive Committee* Our Work
* – Diabetes
* – HIV
* – Oncology
* – Vaccines
* Perspectives
* Confronting Unconscious Bias * A $16 Billion Investment in The Future * From the Military to Merck * Investing in Inclusive Business and Diverse Suppliers * Harnessing Digital Technology for Maternal Health * Helping Protect Generations From Preventable Infectious Diseases * Supporting Our Veterans: A Personal and Professional Commitment * We Can Grow Our Business While Protecting the Health of Our Planet * In the Fight Against Cancer, Progress is Made One Step at a Time * Advancing Oncology Research Through Clinical Trials * Taking Population Health to Merck Employees * How Merck is Working to Preserve One of the Planet’s Most VitalResources - Water
* Clear Communication Must be Part of the Care… and the Cure * Our Pricing Practices: Under the Microscope * Finding New Ways to Create a Healthier and More Sustainable World * When a Blockbuster Medicine Becomes a Generic * A Track Record of Responsible Pricing and Investing in the Next Generation of Inventions * From Pledge to Action: Diversity & Inclusion in Our Workplace * Diversity and Inclusion: Good for Business * Working Together to Create a Sustainable Market for Antibiotics* How We Operate
* – Code of Conduct * Our Values and Standards * Our Values and Standards For External Business Partners* – Compliance
* – Privacy
* – Transparency and Privacy * – Internet Privacy Policy * – Cookie Privacy Commitment * – Cross Border Policy * – Employment Privacy & Data Protection* – Diversity
* – Employee Diversity * – Programs and Partnerships * – Supplier Diversity * Chief Diversity Officer* What We Buy
* Definitions
* Register Potential Supplier * Supplier Diversity * Views and Positions * – Access and Affordability * – Access to Investigational Medicines* – Innovation
* – Quality and Safety * – Sales and Marketing * – Responsible Public Policy and Advocacy * Public Policy Position Statements * Trade Association Memberships* Our History
* Company Fact Sheet* Our People
* Featured Stories
* Meet Merck physician and volunteer Dr. Mo Ali * Our commitment to communities during the COVID-19 pandemic * Antibiotic resistance: the hidden threat lurking behind Covid-19 * Heart failure: A physician’s perspective * How our teams in China tackled early COVID-19 challenges * How Merck is responding to the global pandemic, COVID-19 * Women’s history month – a time to reflect and be inspired * My HPV Cancer Story * Black History Month — a time to reflect and celebrate * Podcast: How Merck is looking back on past epidemics and science to respond to the coronavirus outbreak * 5 ways to support a loved one living with lung cancer * Facing breast cancer three times – a profile of hope * Inside Davos 2020: the world economic forum * Merck joins the World Cancer Day movement to push for progress * Farm to boardroom: Leader Laura Villarreal is determined to keep animals and humans healthy * The power of partnership * Creating Safer Childbirth Cities: Leaning into our values of diversity and inclusion * How craft projects, talent shows and tai chi are helping people manage their diabetes in China * How our Boston Innovation Hub helps us build externalcollaborations
* How you can help slow the threat of antimicrobial resistance * The impact of family in managing type 2 diabetes * How 'hacking' may help solve some of health care's biggestchallenges
* How flexible workspaces are redefining the way we work * Five truths about lung cancer * Merck 2019 third-quarter financial results * Merck Publishes 2018/2019 Corporate Responsibility Report * Merck joins South San Francisco biotech community with innovative research site and hunger for collaboration * Antimicrobial resistance: a problem without a simple answer * A team approach to helping fight cancer * When breast cancer hits home * Inventing for life: passion, purpose and people * Meet Alan Northrup * ‘Embrace the gray areas…and dream big.’ * Meet Beth-Ann Coller * Tackling the U.S. maternal mortality crisis * Powered by inclusion: how we celebrate our diverse workforce * ‘You Never Forget That Day’ * How Jeron’s type 2 diabetes diagnosis motivated him to live ahealthy lifestyle
* How Don Watson builds diversity and inclusion into all aspects ofwork life
* Women in Leadership - Three supply chain leaders share theirstories
* Dr. Maurice Hilleman: The father of modern vaccines * Merck 2019 second-quarter financial results * Progress and purpose: a conversation with Merck scientists and HIVcare providers
* Meet two scientists whose goals are to help end the HIV epidemic * What you need to know about measles * Merck hosts students from INROADS College Links * Patients in remote areas are finding specialized care throughProject ECHO
* Meet our president leading the Asia Pacific region: DortheMikkelsen
* From factory to patient: Merck pilots blockchain project to traceand track drugs
* How Merck's historic discoveries in Palo Alto shape its future inSouth San Francisco
* How we are building a strong foundation in pancreatic cancerresearch
* Rising Star award winner Kara Price shares how she encouragesother women in STEM
* Making the healthy choice the easy choice for our employees* With Love, Me
* Driving melanoma research forward * Understanding melanoma * Meet the nurses who work at Merck * Merck 2019 first-quarter financial results * Merck’s cutting-edge facilities take manufacturing to newheights
* Women in Leadership * Living with and combating infectious diseases * ‘Scientific talent is everywhere, resources are not.’ * Infant Vaccination: A Public Health Success Story * Merck has ambitious goals to protect the environment * The Wonders of Water * Women in Leadership: Raquel Tapia * Advice from Women in Leadership * Helping Moms Safely Deliver Their Babies * Let’s Talk About Kidney Cancer * Pushing Forward in Prostate Cancer Research * Merck 2018 Fourth-Quarter and Full-Year Earnings * Women in Leadership: Geralyn Ritter * Merck Stands United on World Cancer Day * Inspiring People, One Day at a Time * Women in Leadership: Caroline Litchfield* We Are Honored
* Speeding Up Drug Discovery * Where Hope is an Anchor* Meet James Fells
* Dear Cancer Heroes: Honoring People in Clinical Trials * Ovarian cancer – too many lives cut short* Meet Caroline Fox
* Infectious Disease Week * Dr. Cathy Pietanza: ‘Each Day, I’m Reminded of My Patients’ * When Disaster Strikes * Merck Publishes 2017/2018 Corporate Responsibility Report * Fostering Work-Life Balance at Merck * Dave Hull Stands Up To Cancer * The Merck Fellowship for Global Health * Fostering Work-Life Balance at Merck * Meet Rob Garbaccio * Understanding Biomarkers: MicroSatellite Instability High/MisMatchRepair Deficiency
* National Immunization Awareness Month * What Cancers Have in Common: Pushing the Boundaries of Science* Meet John Howe
* Al Alberts, Key Figure in the "Cholesterol Revolution," Dies at 87 * Living with Type 2 Diabetes * Julie Gerberding Honored as 2018 Woman of the Year * Meet Stephanie Barrett * National Infant Immunization Week * Understanding Mumps * A Leader in Immuno-oncology Clinical Research * Meet Luis Zúñiga* HPV Awareness
* Your Cancer Game Plan Challenge* Meet Rebecca Ruck
* Employees Rising to the Occasion * Merck’s Employees Help After Disaster Strikes * Your Cancer Game Plan Lung * A very unique way to grow a family * Merck Publishes 2016/2017 Corporate Responsibility Report * World Diabetes Day 2017 * Meet Angela Jablonski * A Diagnosis of Breast Cancer * Your Cancer Game Plan Mike Schmidt * From Pledge to Action: Diversity & Inclusion in Our Workplace * The Unique Role of Public Policy in Addressing AntimicrobialResistance
* Merck’s Disaster Relief Efforts * Making Positive Choices * Pulling Back the Curtains on Insomnia * Creativity Inside a Shipping Container * Honoring Our Differences * Merck's Response to Hurricane Harvey * Merck Teams Up with Mandy Moore * The Vaccine Pioneers * Merck Stakes a Claim in Cambridge, Massachusetts * Aspen Ideas Festival* Dorothy Robinson
* Erika Carbray
* Nicole Pulli
* 2017 Merck Fellowship for Global Health * Our Legacy - And Future - in American Manufacturing * Merck's IT Organization Expands into Austin, Texas * MECTIZAN Donation Is One for the Record Books * Journey for Control * A Point of View by Dr. Bao Lam * Fighting Some of the World's Toughest Bacterial Infections* Meet Dan Cua
* It Takes a Village * Type 2 Diabetes: A Focus on A1C * May is for Mothers * Pushing to Outpace Superbugs * Merck Announces Enhancements to Family Leave Time * Classical Hodgkin Lymphoma: Facing Cancer in Young Adulthood* World Sleep Day
* BeKindAlways4Noah
* The Merck-Regenstrief Collaboration * Why Drug Discovery is the Foundation of Merck’s Future * How Chronic Hepatitis C is Impacting Our Veterans * Meet Gokul Swaminathan * Merck Honors Research Microbiologist H. Boyd Woodruff, Ph.D. * Merck Uses Amazon Web Services to Develop Voice-Enabled Solutions * Cancer Needs Cures. Still. * Merck Be Well Challenge 2016 — Bringing the Outside In * A Point of View by Adam Schechter, president of Global HumanHealth at Merck
* Your Cancer Game Plan * Merck Foundation Grant Helps Expand Project ECHO * Merck’s Commitment to Prevention and Care for NCDs* Meet Jay Schiller
* Merck Research Laboratories Expands into South San Francisco * Test. Talk. Take. Action. * Bridging the Gap in Diabetes Care * World Diabetes Day 2016 * Meet Harriet Johnson * Merck Employees Surpass Goal of 125,000 Volunteer Hours * _Merck for Mothers_ Pep Talk * Meet Commander Adam Scott* Meet Noreen Rizvi
* Ebola Outbreak
* A Point of View by Dr. Roger Dansey * A Point of View by Dr. Gregory Lubiniecki * Merck’s Susan Shiff Selected * Faces of the Future * Merck Research Laboratories Honored * Living with Breast Cancer* Health Literacy
* A Point of View by Julie Gerberding, M.D., M.P.H.* Meet Paige Cramer
* Merck Releases 2015/2016 Corporate Responsibility Report * How Merck Animal Health Helped to Curb a New Strain of CIV* Women in Science
* Meet Daria Hazuda
* Combating head and neck cancer * Understanding Head and Neck Cancer * HPV and Certain Cancers: What You Need to Know * Meet Arnaub Chatterjee * Fasting and Diabetes * Understanding Diabetes * Living with Type 2 Diabetes * It's Personal Series * Collaborating to Cure* Meet Mike Thien
* Roy Vagelos Honored by American Heart Association * Changing the Statistics * Charting a New Course in Cancer Care * New Approaches to Fighting Cancer * Melanoma... 'Never Walk Alone' * Be Safe In The Sun * America's Diabetes Challenge * World Immunization Week * Merck for Mothers at the Women in the World Summit * Vaccines: Our History, Our Legacy * The Impact of Cancer * Merck’s Commitment to Hepatitis C * Hepatitis C: A Silent Disease and Ongoing Concern * Using Water Wisely * Meet George W. Merck* Heart Disease
* Guided by Research, Inspired by Hope * Why Animal Health Matters* Merck Turns 125
* Cervical Health Awareness Month * Rallying to Meet the Need * William Campbell Wins Nobel Prize * Meet Christopher Kistler * Diversity and Inclusion: Good for Business * Understanding Alzheimer’s Disease* Living with HIV
* Meet Jason Cheung
* Hepatitis C: A Medical — and Social — Diagnosis * The Fight Against Hepatitis C * Saluting Those Who Serve * Lung Cancer: Challenges and Reasons for Hope* Real Invention
* World Diabetes Day* Lung Cancer
* Refugee and Migrant Relief Efforts * What is C. difficile * Beyond Tired? So Are They... * Meet Alexander Buitrago Santanilla * Ken Frazier Receives Lifetime Achievement Award * Merck Employees Walk to End Alzheimer’s * Ken Frazier at the Clinton Global Initiative * Helping to Advance a New Set of UN Global Goals * Merck Fellowship for Global Health * 2014 Corporate Responsibility Report * New Therapies to Attack Infections * The Race Against Resistance * Identifying the Next Generation of Antibacterial Therapies * The Fight Against Antimicrobial Resistance * Mectizan Donation Program * Meet Paul Reichert * Merck for Mothers at TEDWomen * Meet Spencer Dreher * Merck and HIV/AIDS * Fasting and Diabetes * Merck's Rule the Real Talk Campaign * Meet Daisy Richardson* Art for All
* MSD in Japan: Bringing Back the Beach * A Commitment to Diabetes Research * A Silent Disease and Growing Concern* Meet Tim Cernak
* Melanoma ... Never Walk Alone * Be Safe in the Sun * May is for Mothers * Bone Health Awareness * America's Diabetes Challenge * Pushing to Outpace Superbugs * The Evolution of Cancer Research * Parasites and Your Pets * Meet Ayesha Sitlani * Every Woman Every Child Event* Everyday Heroes
* New Approaches to Fighting Cancer* Insomnia
* Advancing Oncology Research Through Clinical Trials * Bridging the Gap in Diabetes Care * Closing the Circle on Rabies * Desafiando la Diabetes * Understanding Diabetes * Helping Empower Women Living with HIV * Diabetes and Travel * Vaccines: Our History, Our Legacy * The Impact of Cancer * A Point of View by Eric Rubin, M.D. * Making a Difference* Products
×
Products
* Products
* Product List A-Z
* Vaccines & Prescribing Information * Prescription Products & Prescribing Information * Oncology Products & Prescribing Information* Animal Health
* Access and Patient Assistance* Product Patents
* Authorized Distributors * Vaccine Contracted Distributors * Safety Data Sheets (SDS)* Research
×
Research
* Research
* Candidate Discovery * Preclinical Development * Clinical Development * Regulatory Review and Ongoing Monitoring * Our People, Our Culture * – The MRL Postdoctoral Research Fellow Program* Our R&D Process
* What We're Working On* Pipeline
* Clinical Trials
* Invent with Us
* Discover Where Our Research Happens* Licensing
×
Licensing
* Licensing
* Newsroom
×
Newsroom
* Newsroom
* News Releases
* – Prescription Medicine News * – Consumer Care News* – Vaccine News
* – Research & Development News * – Corporate News * – Financial News * – Corporate Responsibility News * – Animal Health News * Information Centers* – Diabetes
* – Ebola
* – Oncology
* Company Statements* Media Center
* Company Snapshot
* Social Media
* Careers
×
Careers
* Careers
* Search Jobs
* Our Divisions
* – Research & Development * – Manufacturing & Supply* – Human Health
* – Animal Health
* – Global Support Functions * Diversity & Inclusion * Compensation & Benefits * Veterans Opportunities * Student Opportunities* How We Hire
* MSD Careers
* Talent Community
* Events
* Investors
×
Investors
* Investors
* Product Pipeline
* News
* Events & Presentations* Stock Info
* – Stock Quote & Chart * – Historical Price Look-up * – Investment Calculator * – Dividend History* – Stock Splits
* – Analyst Coverage* Financials
* – Quarterly Reports * – Annual Reports & Proxy* – SEC Filings
* Governance
* Investor Resources* – FAQs
* – Stockholder Services * – Corporate Responsibility * – Information Request * – Sign up for Email Alerts* – Other
* – Contact Us
Menu
MENU
Home / / Contact Us / About Us/ Our Work / Our
People / Research
/ Research
*
*
*
*
*
*
MEET MERCK PHYSICIAN AND VOLUNTEER DR. MO ALI: “WE ARE HERE TO SERVE THE PEOPLE WE LOOK AFTER, I CANNOT STAND BY AND WATCH THIS.”LEARN MORE
MEDICAL PROFESSIONALS ACROSS MERCK, PFIZER, AND ELI LILLY ACTIVATE VOLUNTEER CONTINGENCY PLANS AMID COVID-19 PANDEMICLEARN MORE
YOUR QUESTIONS ANSWERED: HOW MERCK IS RESPONDING TO THE COVID-19PANDEMIC
LEARN MORE
OUR COMMITMENT TO COMMUNITIES DURING THE COVID-19 PANDEMICLEARN MORE
ANTIBIOTIC RESISTANCE: THE HIDDEN THREAT LURKING BEHIND COVID-19LEARN MORE
MERCK DONATES A HALF A MILLION MASKS TO SUPPORT COVID-19 EMERGENCY RESPONSE IN NEW YORK CITYLEARN MORE
Previous Next
LATEST NEWS
SEE ALL LATEST NEWS
__ SOCIAL @MERCK
*
* Connect with Us:
*
*
*
*
*
*
OTHER MERCK SITES
* Merck for Mothers
* MerckHelps
* MSD.com
* Clinical Trials
* Corporate Responsibility * Merck Corporate Responsibility website __ * Transparency Disclosures __ * California Supply Chains Act __ * Merck Animal Health* Merck Manuals
* Merck Connect
* Access and Patient Assistance * Univadis (a service of Merck subsidiary Aptus Health) Copyright © 2009-2020 Merck Sharp & Dohme Corp., a subsidiary of MERCK & CO., INC. All rights reserved. * Forward-Looking Statement* Privacy
* Terms of Use
* Site Map
×Close
FORWARD-LOOKING STATEMENT FORWARD-LOOKING STATEMENT OF MERCK & CO., INC., KENILWORTH, NJ, USA This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2018 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).NO DUTY TO UPDATE
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after thepresentation date.
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0